What could you do with 15 letters?
Show her the world.
Give your patients a chance to gain as many lines as possible.
Lucentis is the first and only therapy proven to deliver a 3-line gain in up to 41% of patients at 2 years with monthly dosing (vs 4% with sham and 6% withverteporfin PDT)
Nearly all Lucentis-treated patients – 90% – maintained vision at 2 years (vs 53% with sham and 66% with verteporfin PDT)
Brand name: Lucentis
Generic name/category: Ranibizumab, Ophtalmology
Company: Genentech
Country/Market: USA, North America
Indication(s)/use: neovascular (wet) age-related macular degeneration
Target: Healthcare Professionals (HCP)
Tagline: Lines gained. Lives changed.
Publication: Ophtalmology Times June 2009
To see all of this brand’s ads on AdPharm, click here
Tags: binoculars, blue, english, female, male, man, marketing, orange, pinned letters, print advertising, single-page, usa, valley, your-patients
Business Week – Drug Marketing
Business Week – Pharma Marketing
Cafe Pharma
Clinical Trials.gov
FDA on Twitter
Pharma Live
Pharma Voice